Robert A Wermers

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice
    Laurie J Pencille
    Knowledge and Encounter Research Unit, Mayo Clinic, Rochester, MN, USA
    Trials 10:113. 2009
  2. ncbi Incidence and clinical spectrum of thiazide-associated hypercalcemia
    Robert A Wermers
    Division of Endocrinology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Am J Med 120:911.e9-15. 2007
  3. ncbi Morbidity and mortality associated with Paget's disease of bone: a population-based study
    Robert A Wermers
    Division of Endocrinology, Metabolism and Nutrition, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Bone Miner Res 23:819-25. 2008
  4. ncbi Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy
    Robert A Wermers
    Department of Internal Medicine, Division of Endocrinology, Diabetes, Nutrition, and Metabolism, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    Clin Infect Dis 52:604-11. 2011
  5. ncbi Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease
    Robert A Wermers
    Division of Endocrinology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    J Bone Miner Res 21:171-7. 2006
  6. ncbi Osteoporosis associated with megestrol acetate
    Robert A Wermers
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:1557-61. 2004
  7. ncbi Acute pancreatitis in primary hyperparathyroidism: a population-based study
    Teck Kim Khoo
    Division of Endocrinology, Metabolism, and Nutrition, Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 94:2115-8. 2009
  8. ncbi Suppressibility of parathyroid hormone in primary hyperparathyroidism
    Teck Kim Khoo
    Department of Internal Medicine and the Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Endocr Pract 13:785-9. 2007
  9. ncbi Percutaneous parathyroid ethanol ablation in patients with multiple endocrine neoplasia type 1
    Mark W Veldman
    Department of Radiology, Mayo Clinic, 200 1st St, SW, Rochester, MN 55902, USA
    AJR Am J Roentgenol 191:1740-4. 2008
  10. ncbi Depression in primary hyperparathyroidism: prevalence and benefit of surgery
    Rachel P Espiritu
    Department of Internal Medicine and Division of Endocrinology, Diabetes, Nutrition, and Metabolism, Mayo College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 96:E1737-45. 2011

Collaborators

Detail Information

Publications17

  1. ncbi Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice
    Laurie J Pencille
    Knowledge and Encounter Research Unit, Mayo Clinic, Rochester, MN, USA
    Trials 10:113. 2009
    ..e., absence of contamination) of patient-level randomization (vs. cluster randomization) in pilot trials of decision aid efficacy...
  2. ncbi Incidence and clinical spectrum of thiazide-associated hypercalcemia
    Robert A Wermers
    Division of Endocrinology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Am J Med 120:911.e9-15. 2007
    ..The study determines the incidence of thiazide-associated hypercalcemia and clarifies its clinical features and natural history...
  3. ncbi Morbidity and mortality associated with Paget's disease of bone: a population-based study
    Robert A Wermers
    Division of Endocrinology, Metabolism and Nutrition, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Bone Miner Res 23:819-25. 2008
    ..We examined morbidity and mortality associated with this condition in a large inception cohort of Olmsted County, MN, residents with a new diagnosis of Paget's disease from 1950 through 1994...
  4. ncbi Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy
    Robert A Wermers
    Department of Internal Medicine, Division of Endocrinology, Diabetes, Nutrition, and Metabolism, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    Clin Infect Dis 52:604-11. 2011
    ..Elevated plasma and bone fluoride levels were identified. Discontinuation of voriconazole therapy led to improvement in pain and reduced fluoride and alkaline phosphatase levels...
  5. ncbi Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease
    Robert A Wermers
    Division of Endocrinology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    J Bone Miner Res 21:171-7. 2006
    ..The lower rates previously noted persisted, whereas parathyroidectomies at our institution remained high. These data suggest an etiologic factor may be responsible for the peak incidence in the 1970s...
  6. ncbi Osteoporosis associated with megestrol acetate
    Robert A Wermers
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:1557-61. 2004
    ..Further study is warranted to clarify the relationship between megestrol and its potential for adversely affecting the skeleton...
  7. ncbi Acute pancreatitis in primary hyperparathyroidism: a population-based study
    Teck Kim Khoo
    Division of Endocrinology, Metabolism, and Nutrition, Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 94:2115-8. 2009
    ..The association between acute pancreatitis and primary hyperparathyroidism (PHPT) is controversial...
  8. ncbi Suppressibility of parathyroid hormone in primary hyperparathyroidism
    Teck Kim Khoo
    Department of Internal Medicine and the Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Endocr Pract 13:785-9. 2007
    ..To describe an unusual case of pathologically confirmed primary hyperparathyroidism in a patient presenting with severe hypercalcemia and an undetectable parathyroid hormone (PTH) level...
  9. ncbi Percutaneous parathyroid ethanol ablation in patients with multiple endocrine neoplasia type 1
    Mark W Veldman
    Department of Radiology, Mayo Clinic, 200 1st St, SW, Rochester, MN 55902, USA
    AJR Am J Roentgenol 191:1740-4. 2008
    ..CONCLUSION: Ethanol ablation is a viable alternative to reoperation for the management of recurrent primary hyperparathyroidism in patients with MEN1...
  10. ncbi Depression in primary hyperparathyroidism: prevalence and benefit of surgery
    Rachel P Espiritu
    Department of Internal Medicine and Division of Endocrinology, Diabetes, Nutrition, and Metabolism, Mayo College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 96:E1737-45. 2011
    ..Patients with primary hyperparathyroidism (PHP) often report nonspecific symptoms including mood disturbances...
  11. ncbi Changes in bone mineral density after surgical intervention for primary hyperparathyroidism
    Benzon M Dy
    Department of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN
    Surgery 152:1051-8. 2012
    ..We sought to determine bone mineral density improvement after successful surgery and associated factors...
  12. ncbi Increased mortality of patients with diabetes reporting severe hypoglycemia
    Rozalina G McCoy
    Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Diabetes Care 35:1897-901. 2012
    ..We conducted a retrospective study to determine whether patient self-report of severe hypoglycemia is associated with increased mortality...
  13. ncbi Fluoride-related bone disease associated with habitual tea consumption
    Julie E Hallanger Johnson
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:719-24. 2007
    ..Furthermore, fluoride excess should be considered in all patients with a history of excessive tea consumption, especially due to its insidious nature and nonspecific clinical presentation...
  14. ncbi Vitamin D-mediated hypercalcemia in slack skin disease: evidence for involvement of extrarenal 25-hydroxyvitamin D 1alpha-hydroxylase
    Helen Karakelides
    Department of Endocrinology, Metabolism and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    J Bone Miner Res 21:1496-9. 2006
    ..This contrasts with psoriasis and sarcoidosis of the skin, in which overexpression of the enzyme is restricted to keratinocytes and granulomata, respectively...
  15. ncbi Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial
    Victor M Montori
    Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, USA
    Am J Med 124:549-56. 2011
    ..Poor adherence to therapy, perhaps related to unaddressed patient preferences, limits the effectiveness of osteoporosis treatment in at-risk women. A parallel patient-level randomized trial in primary care practices was performed...
  16. ncbi Parathyroid lipoadenomas: a rare cause of primary hyperparathyroidism
    Lisa S Chow
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, College of Medicine, Rochester, Minnesota 55905, USA
    Endocr Pract 12:131-6. 2006
    ..The clinical features of this pathologic entity are similar to those of the more common pathologic variants of parathyroid disease associated with primary hyperparathyroidism...
  17. ncbi Visual vignette. Acute parathyroid crisis due to primary hyperparathyroidism
    Elizabeth H Nora
    Department of Internal Medicine, Mayo Clinic and School of Medicine, Rochester, Minnesota, USA
    Endocr Pract 10:88. 2004